Chemotherapy After Hormone Therapy Fails Leaves Metastatic Breast Cancer Patients With Grim Odds
A study of more than 5,000 US patients with HR-positive/HER2-negative metastatic breast cancer found median survival of only 13.5 months ...
A study of more than 5,000 US patients with HR-positive/HER2-negative metastatic breast cancer found median survival of only 13.5 months ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine